Regeneron (REGN) Tops Q1 EPS by 35c, Updates FY Guidance
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Revenue Growth %: +3.8%
Financial Fact:
Total revenues: 1.22B
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Regeneron (NASDAQ: REGN) reported Q1 EPS of $4.67, $0.35 better than the analyst estimate of $4.32. Revenue for the quarter came in at $1.51 billion versus the consensus estimate of $1.51 billion.
2018 Financial Guidance(3)
The Company's updated full year 2018 financial guidance consists of the following components:
Sanofi collaboration revenue: Sanofi reimbursement of Regeneron commercialization-related expenses | $450 million–$485 million (previously $450 million–$500 million) |
Non-GAAP unreimbursed R&D(2)(4) | $1.230 billion–$1.310 billion (previously $1.230 billion–$1.330 billion) |
Non-GAAP SG&A(2)(4) | $1.325 billion–$1.395 billion (previously $1.350 billion–$1.450 billion) |
Effective tax rate | 15%–18% (previously 15%–19%) |
Capital expenditures | $420 million–$480 million (previously $420 million–$500 million) |
For earnings history and earnings-related data on Regeneron (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
- From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
